Comparative Effectiveness Research Not Aligned with Financial Incentives
Only after one of the trials examined, the Philadelphia Bone Marrow Transplant Group, did practice change. In that study, researchers discovered that bone marrow transplantation added to both conventional and high dose chemotherapy for women with metastatic breast cancer sixth study did not improve survival than chemotherapy.
In fact, there were higher risks of serious side effects from bone marrow transplantation.
"Treatment harms are a potent driver of changes in clinical practice," Timbie says. "That's sort of a common thread, when harms are on the table, usually that is one of the main drivers in changes of practice."
The RAND team suggests that comparative effectiveness researchers should design studies with an eye to successful translation of whatever the findings are.
And they criticized bias that often is found in specialty society guideline development committees, which lack multi-specialty viewpoints and balance. Such committees should have "robust" conflict of interest policies, more complete documentation of the strength of evidence supporting each guideline, and the use of more explicit statements regarding the recommended clinical actions to take," which few now do.
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital
- CNO on Hospital Redesign: 'You Can't Over-Communicate'
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- Some Cancer Hospitals' Quality Data Will Soon Be Public
- CA Powers Up $80M HIE to 'Create Value in the Data'
- TJC Warns Hospitals of Deadly Medical Tubing Mistakes
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- 3 Traits Personality Assessments Can't Reveal
- The secret committee behind our soaring healthcare costs